Related Experiment Videos
Metamizole intolerance and bronchial asthma
1Hacettepe University, School of Medicine, Department of Chest Diseases. Adult Allergy Unit. Ankara. Turkey. gkarakay@hacettepe.edu.tr
Allergologia Et Immunopathologia
|October 25, 2002
Summary
Metamizole intolerance in Turkey presents similar clinical features to aspirin intolerance, particularly in patients with asthma. Bronchospasm and urticaria are common reactions, with cross-reactivity noted.
Area of Science:
- Clinical Pharmacology
- Allergy and Immunology
- Pharmacovigilance
Background:
- Metamizole, a widely used pyrazolone drug in Turkey, is associated with intolerance reactions.
- Understanding metamizole intolerance is crucial, especially concerning its clinical presentation in patients with and without bronchial asthma.
Purpose of the Study:
- To investigate the clinical features of patients experiencing metamizole intolerance.
- To compare these features between patients with and without bronchial asthma.
Main Methods:
- A survey enrolled 264 patients with metamizole intolerance, divided into two groups: Group I (133 with bronchial asthma) and Group II (131 without asthma).
- Data was collected using a standardized questionnaire.
Main Results:
- No significant differences were found in personal atopy, familial atopy, or familial analgesic intolerance between the groups.
- Bronchospasm was a more frequent reaction in the asthma group (75.9%) compared to the non-asthma group (9%), while urticaria was more common in the non-asthma group (64.9%) vs. the asthma group (25.6%).
- Aspirin cross-reactivity was significantly higher in patients with asthma. Safe alternative analgesics were identified for all participants.
Conclusions:
- Metamizole intolerance appears to be a significant issue in Turkey, comparable to aspirin intolerance.
- Clinical manifestations of metamizole intolerance in asthmatic patients resemble those seen with aspirin intolerance.